Fig. 7: Enhancement of the anti-cancer effect of anti-PD-L1 antibodies (Abs) by additional treatment of FimH.
From: Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
BALB/c mice were injected s.c. with 1 × 106 CT26 carcinoma cells. Five days after tumor injection, mice were treated i.p. with 10 mg per kg anti-PD-L1 antibodies (Abs), 2.5 mg per kg of FimH, or a combination of anti-PD-L1 Abs and FimH for every 5 days. a The graph of CT26 tumor growth is shown. (n = 6 mice significance was determined by the log-rank test, mean ± SEM). b Intracellular IFN-γ and TNF-α producing CD8 T cells in the tumor are shown. c Concentration of IFN-γ in cultured medium from AH1A5 peptide-treated tumor-drLN cells. (n = 6 mice, two-way ANOVA, mean ± SEM). d AH1A5 peptide-specific IFN-γ production was measured in tumor drLN by ELISpot analysis. (n = 6 mice, one-way ANOVA, mean ± SEM).
